Explore Our Biomarker Menu

Biomarker:

CHOP (total)

Biological or Clinical Significance:

C/EBP homologous protein (CHOP), also known as growth arrest- and DNA damage-inducible gene 153 (GADD153) is a 29 kDa transcription factor that mediates one of the three arms of unfolded protein response (UPR) adaptation to endoplasmic reticulum stressors. CHOP/GADD153 plays a key role in ER stress-mediated apoptosis and in diseases including diabetes, brain ischemia and neurodegenerative disease.

Since induction of CHOP is involved in the development of various diseases, CHOP-targeted therapies may be useful for these diseases. For instance, suppression of CHOP by RNA interference, decoy oligodeoxynucleotides or drug inhibitors could have a significant therapeutic potential to modulate type I diabetes, brain ischemia and others. On the other hand, overexpression of CHOP may represent a new class of anticancer therapy. Since induction of BiP has been observed in a variety of tumor cells, overexpression of CHOP directed by the BiP promoter may be used as a highly specific therapy for cancer. Further studies on CHOP-mediated apoptosis will provide a basis for new therapeutic approaches to diseases associated with ER stress.

References:

Analyte:

CHOP (total)

Matrix:

Status:

Experienced Running

Sensitivity-LLOQ:

Sensitivity-ULOQ:

platform

MSD-ECL

Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist





    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Immunogenicity

    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.